H.B. Fuller, a 130-year-old industrial adhesives company, just rejected a $1.2 billion offer for one of its core businesses, and the investor pushing that offer is unlikely to walk away quietly.

The offer came from Ancora Holdings Group, an activist investment firm that has been agitating against H.B. Fuller's leadership since May. Ancora's proposal targeted the company's Building Adhesives Solutions unit, which makes the specialty adhesives used in construction and, increasingly, in data centers. The price range Ancora floated was between $1.1 billion and $1.2 billion. H.B. Fuller's board voted unanimously to reject it.

Why the board said no

The company's rejection wasn't just a refusal. It was a rebuttal on three fronts.

First, the price. The board said the offer "significantly undervalues" the unit and sits "substantially below precedent transactions," meaning similar business sales in the adhesives industry have fetched more. That claim has some backing: the building adhesives unit grew organic sales by 6% and operating profit (before interest, tax, and depreciation) by 10% in the most recent quarter. When a business is growing at that pace, and when management expects construction markets to recover while data-center demand adds a new growth channel, a seller has reason to hold out.

Second, the operational complexity of a carve-out. H.B. Fuller's building adhesives unit doesn't sit in a clean, separable box. It shares manufacturing operations with the company's other businesses across more than 30 plants worldwide. Pulling it out, management argues, would destroy real efficiencies that currently benefit the whole company. In plain terms: the sum is worth more than the parts.

Third, Ancora's credibility. The board said the proposal "lacks key details needed to demonstrate" Ancora's ability to actually execute the deal. That's a pointed critique. An unsolicited offer without a clear financing structure or execution plan is easier to dismiss.

What Ancora wants and why it matters

Ancora's campaign started in May, initially targeting H.B. Fuller's decision to acquire Advanced Medical Solutions Group, a UK-based medical adhesives company. That move, in Ancora's view, stretched management's attention and capital in the wrong direction. The Building Adhesives Solutions offer represents an escalation: Ancora has moved from criticizing strategy to putting a number on the table.

That shift matters because it changes the nature of the fight. Criticism is easy to absorb. A specific bid forces a board to respond publicly, explain its reasoning, and defend its valuation in front of shareholders. Every shareholder who owns H.B. Fuller stock now has to decide whether they believe management's growth story or Ancora's argument that $1.2 billion in cash today is the smarter outcome.

Ancora could press further. Activist investors who submit a bid and get rejected often escalate: they seek proxies, rally other shareholders, push for board seats, or simply keep the pressure on until management proves the business is worth more. None of those paths are resolved by a single board rejection.

The bigger picture

What's playing out at H.B. Fuller is a familiar tension in American industrial companies. Activists look at a conglomerate structure and see hidden value waiting to be unlocked through separation. Management looks at the same structure and sees operational integration that Wall Street's simple math doesn't capture. Both arguments can be right in different circumstances, which is what makes these disputes genuinely hard to call.

The outcome here will probably turn on one thing: whether the building adhesives unit's growth story holds up. If construction markets recover the way H.B. Fuller expects, and if data-center demand keeps pulling through, management's case for patience gets stronger with every quarterly result. If growth stalls, Ancora's offer starts looking more reasonable in hindsight, and the pressure on the board intensifies accordingly.

For now, H.B. Fuller has said no. The next move is Ancora's.